Blepharitis Market Research Report - Forecast to 2027

Blepharitis Market Research Report: Type (Anterior Blepharitis, Posterior Blepharitis, Mixed Blepharitis) Treatment (Eye Cleansers, Antibiotic Therapy) Diagnosis (Physical Examination) End User (Hospitals, Specialty Centers)-Forecast till 2027

ID: MRFR/Pharma/4311-HCR | | Region: Global | 100 pages

Blepharitis Market Overview:


Blepharitis is an ophthalmological disorder that causes inflammatory conditions to the eyelid that leads to ocular discomfort and irritation to the eye in all age groups of the population. This eye disorder is caused by various reasons such as bacteria or a skin condition like dandruff from the scalp or overproduction of oil from the eyelid glands. This disorder is not sight-threatening but leads to permanent alterations in the eyelid margin or vision loss from ulceration, superficial keratopathy, and corneal neovascularization.


The two types of blepharitis are anterior and posterior which infect the eyes in various types. The other type, anterior blepharitis infects the eyelid skin, eyelash follicles, and the base of the eyelashes. Posterior blepharitis affects the meibomian glands and gland orifices. This treatment cleanses the eyelid routines daily and uses therapeutics agents that reduce infection and inflammation. Using therapeutics or drugs in the treatment, expand the capabilities of treatment and also enables new diagnostic and treatment applications for the patient. This treatment ensures a better functional ability to cure a few common types of diseases related to the eyes. According to the report of the American Academy of Ophthalmology from the US ophthalmologists and optometrists, 37% to 47% of patients were diagnosed with blepharitis signs.  


The blepharitis market size is expected to grow at a CAGR of 6.5% during the forecast period.


COVID-19 Analysis:


The COVID-19 outbreak has affected all the business sectors across the globe and impacted the economy drastically. The economy is affected by three major reasons like affecting production and demand, creating supply chain and market disruption, and finally by its financial impact on firms and financial markets. To curb the spread of the coronavirus, various governments implemented lockdowns and some other strict regulations.


The lockdown of the COVID-19 has brought effects on various aspects like flight cancellations, transportation bans, quarantines, public places shutdowns like restaurants, theatres, schools, and all indoor events to maintain social distance one from other. These restrictions are implemented in over forty countries and the manufacturing industries of blepharitis are faced various issues like lack of raw materials, shortage of manpower, and supply chain disruptions and stops production which leads to falling in blepharitis. Hence, the halt of production, slowing down of the business confidence, rising panic among the population, people staying in their homes itself results in the declining market of blepharitis. However, after lifting the lockdown, the demand for blepharitis treatment increases due to their benefits.


Market Dynamics:


Drivers:


Increasing demand for healthcare facilities in emerging economies is propelling market growth. Growing prevalence of ophthalmological disorders like dry eye, acne rosacea uveitis, and others. Moreover, government initiatives, increasing demand for advanced treatment, growing awareness regarding eye care among the people, and rising market players for introducing new products for blepharitis treatment are the few factors accelerating the blepharitis market growth.


Increasing the population suffering from blepharitis and the growing emergence of novel drugs are the factors escalating the growth of the blepharitis drug market. Additionally, increasing expenditure on the development of healthcare infrastructure and growing personal disposable income is enhancing the market growth. The advent of high-throughput screening (HTS) for drug discovery to treat ocular diseases is boosting the growth of the market.


Restraint:


Blepharitis treatment is very expensive and limited facilities to implement the treatment are the factors restraining the market growth.


Opportunities:


Increasing the investment in R&D activities, introducing innovations in products, and upgrading the existing products by market players is creating an opportunity to boost the growth of the blepharitis treatment market.


Challenges:


Lack of awareness regarding blepharitis disease and patent expiry of various companies are the major challenges of the market growth.


Study Objectives -



  • To provide specific information about the blepharitis market structure along with various forecast segments and subsegments for the next coming 10 years.

  • To provide the declining factors the growth of the blepharitis market value.

  • To examine the blepharitis market industry analysis based on porter’s five force analysis, factors-price analysis, supply chain analysis, etc.

  • To offer history and future revenue segments and sub-segments of the blepharitis market revenue for the main geographies.

  • To provide the country-level analysis of the current blepharitis market size and future prospective. 

  • To provide country-level analysis of the blepharitis market industry growth by region, form, treatment, diagnosis, and application.

  • To offer the major key players in the market, analyze their core competencies, and draw a global market growth landscape.

  • To study new product developments, mergers, acquisitions, strategic alliances, and global market research.


Segment Overview:


The global blepharitis market has been divided into segments based on type, treatment, diagnosis, end-use, and region.


Based on Type


The blepharitis types are trifurcated into anterior blepharitis, posterior blepharitis, and mixed blepharitis.


Based on Treatment


Blepharitis treatments are classified into three types such as eye cleansers, artificial tears, and antibiotic therapy. Further, antibiotic therapy is sub-segmented into topical antibiotic therapy and oral antibiotic therapy. As oral antibiotic therapy offers anti-inflammatory and lipid regulating properties, ora;l antibiotic therapy is dominating the largest share.


Based on Diagnosis


The blepharitis market based on diagnosis is analyzed into a few types as physical examination, comprehensive eye examination, and others.  


Based on End-user


The blepharitis market end-users are categorized into a few types like specialty centers, hospitals, and others.


Based on Region


Region-wise, the global blepharitis market is divided into four main geographies such as the Americas, Europe, Asia-Pacific, and the Middle East & Africa. Out of these regions, America is dominating the largest market share for the rising incidence of eye disorders and increasing awareness regarding eye care among the population.


Regional Analysis -


Geographically, the blepharitis market based on regions is segmented into four major regions like Asia-Pacific, Europe, the Americas, and the Middle East & Africa. Among them, the American region is holding the maximum blepharitis market share due to the rising incidence of eye disorders, and growing awareness among the population regarding eye care. Moreover, increasing healthcare expenditure and the growing involvement of major key players in developing the product innovations, and increasing government support are boosting the market growth in North America. In 2015, in the US, healthcare spending is increased by 5.8% reaching USD 3.2 trillion according to the report of the Centers for Medicare & Medicaid Services.


Due to the presence of a large pool of market players introducing the new product launches and increasing skilled medical professionals, coupled with increasing demand for advanced healthcare infrastructure, Europe is holding the second-largest share in the global market. The Organization for Economic Co-operation and Development (OECD) states that in 2014, the healthcare expenditure in Germany was EUR 321 billion which enhances the market growth in this region. Asia-Pacific is said to be the fastest-growing region for the growing population which leads to the increasing patient population and prevalence of eye disorders. Due to lack of awareness and limited treatment facilities, the Middle East & Africa is expected to hold the least market growth.


Competitive Landscape


The prominent key players in the blepharitis market outlook are the following:



  • Scope Ophthalmics Ltd

  • Novartis AG

  • InSite Vision Incorporated

  • Thea Pharmaceuticals Limited

  • Galderma S.A.

  • NovaBay Pharmaceuticals, Inc.

  • Merck & Co.

  • Perrigo Laboratories


Recent Developments



  • One of the leading technology research and advisory companies, Technavio focuses on emerging trends, research, development of effective strategies and offers actionable insights to increase their company’s potential in the market.

  • The topmost key player, Technavio introduced the innovation of the global blepharitis drugs market named Novel Drug Formulation which is a targeted topical treatment of the eyelid margins for patients along with acute exacerbations of blepharitis.


Report Overview:


This global blepharitis market research includes the Market Overview, COVID-19 analysis, Market Dynamics, Study Objectives, Segment Overview, Regional Analysis, Competitive Landscape, Recent developments, Segmentation Table, and FAQs. The market scenario includes the blepharitis market drivers, restraints, challenges, and opportunities. The blepharitis market forecast segments are type, treatment, diagnosis, end-use, and region.


 



Report Scope:
Report Attribute/Metric Details
  Market Size   Significant Value
  CAGR   2018-2023: ~6.5%
  Base Year   2019
  Forecast Period   2027
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Type, treatment, diagnosis, and end user
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   InSite Vision Incorporated, NovaBay Pharmaceuticals, Inc., Scope Ophthalmics Ltd, Thea Pharmaceuticals Limited, Perrigo Laboratories, Merck & Co., Galderma S.A., and Novartis AG.
  Key Market Opportunities   Involvement of leading players in new product development
  Key Market Drivers

  • Rising prevalence of ophthalmological disorders, such as dry eye, uveitis
  • Rising demand for advanced treatment
  • Increasing awareness among mass regarding eye care


  • Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :


    Blepharitis is an ophthalmological disorder which causes inflammation of the eyelids, leading to irritation of the eye.

    Blepharitis Market is expected to exhibit a strong 6.5% CAGR over the forecast period till 2027.

    Increasing awareness about eye diseases is the major driver for the Blepharitis Market.

    Americas hold a dominant 45% share in the global Blepharitis Market.

    Leading players in the Blepharitis include InSite Vision Inc., NovaBay, and Scope Ophthalmics, among others.

    Table of Content

    1. Report Prologue

    2. Market Introduction

    2.1 Definition

    2.2 Scope of the Study

    2.2.1 Research Objective

    2.2.2 Assumptions

    2.2.3 Limitations

    3. Research Methodology

    3.1 Introduction

    3.2 Primary Research

    3.3 Secondary research

    3.4 Market Size Estimation

    4. Market Dynamics

    4.1 Drivers

    4.2 Restraints

    4.3 Opportunities

    4.4 Challenges

    4.5 Macroeconomic Indicators

    4.6 Technology Trends & Assessment

    5. Market Factor Analysis

    5.1 Porter’s Five Forces Analysis

    5.1.1 Bargaining Power of Suppliers

    5.1.2 Bargaining Power of Buyers

    5.1.3 Threat of New Entrants

    5.1.4 Threat of Substitutes

    5.1.5 Intensity of Rivalry

    5.2 Value Chain Analysis

    5.3 Investment Feasibility Analysis

    5.4 Pricing Analysis

    6. Global Blepharitis Market, by Type

    6.1 Introduction

    6.2 Anterior Blepharitis

    6.2.1 Market Estimates & Forecast, 2020–2027

    6.3 Posterior Blepharitis

    6.3.1 Market Estimates & Forecast, 2020–2027

    6.4 Mixed Blepharitis

    6.4.1 Market Estimates & Forecast, 2020–2027

    7. Global Blepharitis Market, by Diagnosis

    7.1 Introduction

    7.2 Physical Examination

    7.2.1 Market Estimates & Forecast, 2020–2027

    7.3 Comprehensive Eye Examination

    7.3.1 Market Estimates & Forecast, 2020–2027

    7.4 Others

    7.4.1 Market Estimates & Forecast, 2020–2027

    8. Global Blepharitis Market, by Treatment

    8.1 Introduction

    8.2 Eye Cleansers

    8.2.4 Market Estimates & Forecast, 2020–2027

    8.3 Artificial Tears

    8.3.1.1 Market Estimates & Forecast, 2020–2027

    8.4 Antibiotic Therapy

    8.4.1 Topical Antibiotic Therapy

    8.4.2 Oral Antibiotic Therapy

    8.4.3 Market Estimates & Forecast, 2020–2027

    9. Global Blepharitis Market, by End-User

    9.1 Introduction

    9.2 Hospitals

    9.2.1 Market Estimates & Forecast, 2020–2027

    9.3 Specialty Centers

    9.3.1 Market Estimates & Forecast, 2020–2027

    9.4 Others

    9.4.1 Market Estimates & Forecast, 2020–2027

    10 Global Blepharitis Market, by Region

    10.1 Introduction

    10.2 Americas

    10.2.1 North America

    10.2.1.1 U.S.

    10.2.1.2 Canada

    10.2.2 South America

    10.3 Europe

    10.3.1 Western Europe

    10.3.1.1 Germany

    10.3.1.2 France

    10.3.1.3 U.K.

    10.3.1.4 Italy

    10.3.1.5 Spain

    10.3.1.6 Rest of Western Europe

    10.3.2 Eastern Europe

    10.4 Asia Pacific

    10.4.1 Japan

    10.4.2 China

    10.4.3 India

    10.4.4 Australia

    10.4.5 Republic of Korea

    10.4.6 Rest of Asia Pacific

    10.5 The Middle East & Africa

    10.5.1 United Arab Emirates

    10.5.2 Saudi Arabia

    10.5.3 Oman

    10.5.4 Kuwait

    10.5.5 Qatar

    10.5.6 Rest of the Middle East & Africa

    11 Company Landscape

    11.1 Introduction

    11.2 Market Share Analysis

    11.3 Key Development & Strategies

    11.3.1 Key Developments

    12 Company Profiles

    12.1 Scope Ophthalmics Ltd

    12.1.1 Company Overview

    12.1.2 Product Overview

    12.1.3 Financials

    12.1.4 SWOT Analysis

    12.2 NovaBay Pharmaceuticals, Inc.

    12.2.1 Company Overview

    12.2.2 Product Overview

    12.2.3 Financial Overview

    12.2.4 Key Developments

    12.2.5 SWOT Analysis

    12.3 Thea Pharmaceuticals Limited

    12.3.1 Company Overview

    12.3.2 Product Overview

    12.3.3 Financial Overview

    12.3.4 Key Development

    12.3.5 SWOT Analysis

    12.4 Perrigo Laboratories

    12.4.1 Company Overview

    12.4.2 Product/Business Segment Overview

    12.4.3 Financial Overview

    12.4.4 Key Development

    12.4.5 SWOT Analysis

    12.5 Merck & Co.

    12.5.1 Company Overview

    12.5.2 Product Overview

    12.5.3 Financial overview

    12.5.4 Key Developments

    12.6 Galderma S.A.

    12.6.1 Company Overview

    12.6.2 Product Overview

    12.6.3 Financial Overview

    12.6.4 Key Developments

    12.7 Novartis AG

    12.7.1 Overview

    12.7.2 Product Overview

    12.7.3 Financials

    12.7.4 Key Developments

    12.7.5 SWOT Analysis

    12.8 Others

    13 MRFR Conclusion

    13.1 Key Findings

    13.1.1 From CEO’s View Point

    13.1.2 Unmet Needs of the Market

    13.2 Key Companies to Watch

    13.3 Prediction of Pharmaceutical Industry

    14 Appendix

    LIST OF TABLES

    Table 1 Blepharitis Industry Synopsis, 2020–2027

    Table 2 Global Blepharitis Market Estimates and Forecast, 2020–2027, (USD Million)

    Table 3 Global Blepharitis Market, by Region, 2020–2027, (USD Million)

    Table 5 Global Blepharitis Market, by Treatment, 2020–2027, (USD Million)

    Table 6 Global Blepharitis Market, by Diagnosis, 2020–2027, (USD Million)

    Table 7 Global Blepharitis Market, by End-User, 2020–2027, (USD Million)

    Table 8 North America Blepharitis Market, by Treatment, 2020–2027, (USD Million)

    Table 9 North America Blepharitis Market, by Diagnosis, 2020–2027, (USD Million)

    Table 10 North America Blepharitis Market, by End-User, 2020–2027, (USD Million)

    Table 11 US Blepharitis Market, by Treatment, 2020–2027, (USD Million)

    Table 12 US Blepharitis Market, by Diagnosis, 2020–2027, (USD Million)

    Table 13 US Blepharitis Market, by End-User, 2020–2027, (USD Million)

    Table 14 Canada Blepharitis Market, by Treatment, 2020–2027, (USD Million)

    Table 15 Canada Blepharitis Market, by Diagnosis, 2020–2027, (USD Million)

    Table 16 Canada Blepharitis Market, by End-User, 2020–2027, (USD Million)

    Table 17 South America Blepharitis Market, by Treatment, 2020–2027, (USD Million)

    Table 18 South America Blepharitis Market, by Diagnosis, 2020–2027, (USD Million)

    Table 19 South America Blepharitis Market, by End-User, 2020–2027, (USD Million)

    Table 20 Europe Blepharitis Market, by Treatment, 2020–2027, (USD Million)

    Table 21 Europe Blepharitis Market, by Diagnosis, 2020–2027, (USD Million)

    Table 22 Europe Blepharitis Market, by End-User, 2020–2027, (USD Million)

    Table 23 Western Europe Blepharitis Market, by Treatment, 2020–2027, (USD Million)

    Table 24 Western Europe Blepharitis Market, by diagnosis, 2020–2027, (USD Million)

    Table 25 Western Europe Blepharitis Market, by End-User, 2020–2027, (USD Million)

    Table 26 Eastern Europe Blepharitis Market, by Treatment, 2020–2027, (USD Million)

    Table 27 Eastern Europe Blepharitis Market, by diagnosis, 2020–2027, (USD Million)

    Table 28 Eastern Europe Blepharitis Market, by End-User, 2020–2027, (USD Million)

    Table 29 Asia Pacific Blepharitis Market, by Treatment, 2020–2027, (USD Million)

    Table 30 Asia Pacific Blepharitis Market, by diagnosis, 2020–2027, (USD Million)

    Table 31 Asia Pacific Blepharitis Market, by End-User, 2020–2027, (USD Million)

    Table 32 Middle East & Africa Blepharitis Market, by Treatment, 2020–2027, (USD Million)

    Table 33 Middle East & Africa Blepharitis Market, by diagnoses, 2020–2027, (USD Million)

    Table 34 Middle East & Africa Blepharitis Market, by End-User, 2020–2027, (USD Million)


    LIST OF FIGURES

    Figure 1 Research Process

    Figure 2 Segmentation for Global Blepharitis Market

    Figure 3 Segmentation Market Dynamics for Blepharitis Market

    Figure 4 Global Blepharitis Market Share, by Treatment 2020

    Figure 5 Global Blepharitis Market Share, by Diagnosis 2020

    Figure 6 Global Blepharitis Market Share, by End-User, 2020

    Figure 7 Global Blepharitis Market Share, by Region, 2020

    Figure 8 North America Blepharitis Market Share, by Country, 2020

    Figure 9 Europe Blepharitis Market Share, by Country, 2020

    Figure 10 Asia Pacific Blepharitis Market Share, by Country, 2020

    Figure 11 Middle East & Africa Blepharitis Market Share, by Country, 2020

    Figure 12 Global Blepharitis Market: Company Share Analysis, 2020 (%)

    Figure 13 NovaBay Pharmaceuticals, Inc: Key Financials

    Figure 14 NovaBay Pharmaceuticals, Inc: Segmental Revenue

    Figure 16 NovaBay Pharmaceuticals, Inc: Geographical Revenue

    Figure 17 Scope Ophthalmics Ltd.: Key Financials

    Figure 18 Scope Ophthalmics Ltd.: Segmental Revenue

    Figure 19 Scope Ophthalmics Ltd.: Geographical Revenue

    Figure 20 Thea Pharmaceuticals Limited: Key Financials

    Figure 21 Thea Pharmaceuticals Limited: Segmental Revenue

    Figure 22 Thea Pharmaceuticals Limited: Geographical Revenue

    Figure 23 Novartis AG: Key Financials

    Figure 24 Novartis AG: Segmental Revenue

    Figure 25 Novartis AG: Geographical Revenue

    Figure 26 Perrigo Laboratories: Key Financials

    Figure 27 Perrigo Laboratories: Segmental Revenue

    Figure 28 Perrigo Laboratories. Geographical Revenue

    Figure 29 Ardelyx, Inc.: Key Financials

    Figure 30 Ardelyx, Inc.: Segmental Revenue

    Figure 31 Ardelyx, Inc.: Geographical Revenue

    Figure 32 Novartis AG. Key Financials

    Figure 33 Novartis AG. Segmental Revenue

    Figure 34 Novartis AG. Geographical Revenue